Safety And Efficacy Of Weekly Administration Of S-8184 Paclitaxel Injectable Emulsion In Second Line Treatment Of Patients With Locally Advanced, Metastatic, Or Recurrent Transitional Cell Carcinoma Of The Urothelium.

Trial Profile

Safety And Efficacy Of Weekly Administration Of S-8184 Paclitaxel Injectable Emulsion In Second Line Treatment Of Patients With Locally Advanced, Metastatic, Or Recurrent Transitional Cell Carcinoma Of The Urothelium.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sonus Pharmaceuticals
  • Most Recent Events

    • 14 Nov 2008 OncoGenex Pharmaceuticals reported as a trial sponsor by ClinicalTrials.gov.
    • 14 Nov 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 06 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top